Abstract
Existing research demonstrates that breast cancer survivors (BCS) report poor sleep as a side effect of estrogen deprivation therapy (EDT) (Berkowitz et al, 2021; Van Dyk et al, 2021; Martin et al, 2021). Despite their potential importance, validated & objective measures of sleep are not yet widely incorporated into breast cancer research. This study aimed to employ actigraph technology to capture real time objective sleep data in a population of BCS on EDT. In addition, surveys captured patient demographics and self-reported sleep data to allow comparison between objective sleep quality and subjective patient reported outcomes in BCS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
